Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human CDKN2B Antikörper:
anti-Mouse (Murine) CDKN2B Antikörper:
anti-Rat (Rattus) CDKN2B Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Polyclonal CDKN2B Primary Antibody für ICC, IF - ABIN407770
Siddiqi, Terry, Matushansky: Hiwi mediated tumorigenesis is associated with DNA hypermethylation. in PLoS ONE 2012
Human Polyclonal CDKN2B Primary Antibody für ELISA, WB - ABIN560313
Ratovitski: Phospho-?Np63?-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death. in FEBS letters 2013
Human Polyclonal CDKN2B Primary Antibody für ELISA, WB - ABIN4342269
Geyer: Strategies to re-express epigenetically silenced p15(INK4b) and p21(WAF1) genes in acute myeloid leukemia. in Epigenetics 2010
E2F1 (zeige E2F1 Antikörper) induces TINCR transcriptional activity and accelerates gastric cancer progression via activation of TINCR/STAU1 (zeige STAU1 Antikörper)/CDKN2B signaling axis.
ANRIL may reduce p15INK4B expression through inhibiting TGF-beta (zeige TGFB1 Antikörper)/Smad (zeige SMAD1 Antikörper) signaling pathway, promoting invasion and metastasis of TC cells, and the silencing of ANRIL inhibits the invasion and metastasis of TPC-1 (zeige TPCN1 Antikörper) cells
single nucleotide polymorphisms within the CDKN2A/2B region affect pancreatic cancer risk
The results of this study suggest an association between CDKN2A/2B gene rs10811661 polymorphism and gestational diabetes mellitus.
Among 8 SNPs in 3 loci that showed at least nominal association (P < 5.00E-02) in the primary cohort, a representative SNP for each loci (rs2157719 for CDKN2B-AS1 (zeige PTGDR Antikörper), rs33912345 for SIX6 (zeige SIX6 Antikörper), and rs9913911 for GAS7 (zeige GAS7 Antikörper)) were selected
The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia
The summary of evidences suggesting that RD(INK4/ARF) enhancer deletion represents a novel mutation in the INK4-ARF locus independent of well-known p15, p16, p14ARF alterations.
Results show that expression of CDKN2B was reduced significantly in colorectal cancer (CRC (zeige CALR Antikörper)) and its promotor is targeted by miR (zeige MLXIP Antikörper)-18b which controls its regulation.
Mechanistic investigations demonstrated that BLACAT1 had a key role in G1/G0 arrest, and showed that BLACAT1 can repress p15 expression by binding to EZH2 (zeige EZH2 Antikörper), thus contributing to the regulation of CRC (zeige CALR Antikörper) cell cycle and proliferation. Our results suggest that BLACAT1, as a cell cycle regulator, may serve as a potential target for colon cancer prevention and treatment in human CRC (zeige CALR Antikörper)
The current study supports a relevant role for p15, p16, and DAPK (zeige DAPK1 Antikörper) hypermethylation in the genesis of the plasma cell neoplasm. DAPK (zeige DAPK1 Antikörper) hypermethylation also might be an important step in the progression from MGUS to MM.
miR (zeige MLXIP Antikörper)-541 contributes to microcystin-LR-induced testicular toxicity by regulating the expression of p15 and promoting apoptosis.
The expression of three tumor suppressor genes encoded in the INK4/ARF locus (p15(INK4b), p16(INK4a), and p19(ARF)) was decreased in E6AP (zeige ube3a Antikörper)(-/-) embryo fibroblasts.
Data show that the Wnt-effector hepatocyte nuclear factor 1-alpha (Tcf1) is recruited to and triggers transcription of the Ink4/Arf tumor suppressor locus, such as as p15Ink4b, p16Ink4a and p19Arf.
Loss of Nf2 (zeige NF2 Antikörper) and Cdkn2a/b have synergistic effects with PDGF-B (zeige PDGFB Antikörper) overexpression promoting meningioma malignant transformation.
Loss of CDKN2B may not only promote cardiovascular disease through the development of atherosclerosis but may also impair TGFbeta (zeige TGFB1 Antikörper) signaling and hypoxic neovessel maturation.
Control of CD8 (zeige CD8A Antikörper) T cell proliferation and terminal differentiation by active STAT5 (zeige STAT5A Antikörper) and CDKN2A/CDKN2B.
Radiation-induced double strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate high-grade gliomas that are commonly driven by Met amplification and activation.
When overexpressed in naked mole rat or human cells, pALT(INK4a/b) has stronger ability to induce cell-cycle arrest than either p15(INK4b) or p16(INK4a).
Cdk4 (zeige CDK4 Antikörper) and Cdk6 (zeige CDK6 Antikörper) cooperate in hematopoietic tumor development and suggest a role for Cdk6 (zeige CDK6 Antikörper) in sequestering INK4 proteins away from Cdk4 (zeige CDK4 Antikörper).
Data indicate that loss of cyclin-dependent kinase inhibitor p15 (p15Ink4b) collaborates with oncogene (zeige RAB1A Antikörper) fusion protein Nup98 (zeige NUP98 Antikörper)-HoxD13 (zeige HOXD13 Antikörper) transgene in the development of predominantly myeloid neoplasms.
This gene lies adjacent to the tumor suppressor gene CDKN2A in a region that is frequently mutated and deleted in a wide variety of tumors. This gene encodes a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, and prevents the activation of the CDK kinases, thus the encoded protein functions as a cell growth regulator that controls cell cycle G1 progression. The expression of this gene was found to be dramatically induced by TGF beta, which suggested its role in the TGF beta induced growth inhibition. Two alternatively spliced transcript variants of this gene, which encode distinct proteins, have been reported.
Cyclin-dependent kinase 4 inhibitor B
, CDK inhibitory protein
, CDK4B inhibitor
, cyclin-dependent kinase 4 inhibitor B
, cyclin-dependent kinases 4 and 6 binding protein
, multiple tumor suppressor 2
, p14_CDK inhibitor
, p15 CDK inhibitor
, cyclin-dependent kinase inhibitor p15
, cyclin-dependent kinase inhibitor p15INK4b
, cyclin-dependent kinase inhibitor protein
, Cyclin dependent kinase inhibitor 2B (p15, inhibits CDK4)
, cyclin dependant kinase inhibitor
, cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
, cyclin-dependent kinase inhibitor 2B
, cyclin-dependent kinase inhibitor 2B (melanoma, p16, inhibits CDK4)
, p15INK4b tumor suppressor